EPHA1 and cancer: Due to the intermediate-to-low mutation frequencies of EPH receptors in cancer, we devised a strategy incorporating pan-cancer pan-EPH mutations and 3D-structure analyses of EPH receptors to maximise detection of mutational hotspots and clusters.